Clinical Trial Search

Primary: Number of Patients With no Disease Activity at Week 16 in the Study Eye — 89 Participants

Primary: Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants — 7.61; 9.18; 6.02; 6.10 BCVA Letters — p=0.5244

Primary: Caliber of Choroidal New Vessel (CNV) — 43.53 micrometer

Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…

Primary: Number of Participants With Ocular Adverse Events — 418; 56; 96; 59 participants

Primary: Percentage Change in Choroidal Neovascularization (CNV) Lesion Area Measured by Optical Coherence Tomography-Angiograph (OCT-A) From Baseline to Week 12 — -79.29 %…

Primary: Percentage of Patients With Ocular Adverse Events (AEs) in the Study Eye — 48.5; 38.9 Percentage of Participants

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Month 3 — .3; 6.8; 7.6 Letters

Primary: Change From Baseline at Week 48 in Best-Corrected Visual Acuity in Study Eye — 9.9; 10.9 Letters Read — p=0.006

Primary: Mean Change From Baseline in Best-corrected Visual Acuity of the Study Eye at Month 12 — 4.9; 3.8; 8.3 letters

Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants

Primary: Number of Subjects With No Cells Observed Following Slit Lamp Examination From Baseline to Week 8 — 23; 21; 23; 21 Participants

Primary: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12 — 53.7; 54.6; 54.8; 59.0 Letters

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…

Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye to Month 2 — 9.5; -0.4 letters — p=<0.001

Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) — 5.5; 5.9 Letters correctly read

Primary: Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score — 7.2 letters

Primary: Primary Outcome: Change in Visual Acuity (LogMAR Letters) From Baseline to Detection of Choroidal Neovascularization — -7.4; -12.6 LogMAR letters (ETDRS)

Primary: Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 6 in Group B — 47.6; 48.1; 55.7; 57.1 Number of Letters

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 — 10.1; 9.2; 8.2; 8.6 Letters

Primary: Number of Subjects With Positive LUCENTIS® Retreatment Status at Day 84 — 25; 25 Participants

Primary: Change From Baseline in CRT as Measured by SD-OCT on Day 29 — 44.0 μm

Primary: Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye — 55.4; 55.8; 54.7; 66.0 Letters

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye — 6.9; 7.6 letters — p=<0.0001

Primary: Vision — 0.16 logMAR

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 5.2; 5.6; 5.4…

Primary: Highest Tolerated Dose (HTD) of AGN-150998 — 4.2 mg

Primary: Number of Participants With Systemic Drug-related Adverse Events — 3; 0 participants

Primary: Change in BCVA as Measured by the ETDRS Letter Score — -2.1; -0.4 Letters correctly read — p=0.0162

Primary: The Number of Patients With no Fluid on OCT — 10 participants